![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
SVR Durability: HCV Patients Treated with IFN-Free DAA Regimens
|
|
|
These data reflect 6 studies with sofosbuvir/Rbv or Harvoni conducted by the DC based NIH group, 85% of study participants are African-Americans, 69% coinfected, 31% monionfected, 82% CT/TT, 25% fibrosis 3/4 HAI Score.
Reported by Jules Levin
CROI 2015 Feb 23-26, Seattle, WA
Aurielle Thomas1, Sarah Kattakuzhy2, Sara Jones3, Anita Kohli4, Eleanor Wilson2, Angie Price2, Rachel Silk2, Zayani Sims4, Anu Osinusi5, Shyam Kottilil2
1 Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 2Division of Infectious Diseases, Institute of Human Virology, University of Maryland, 3Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., 4Critical Care Medicine Department, National Institutes of Health Clinical Center, Frederick National Laboratory for Cancer Research, 5Gilead Sciences, Inc., Foster City, CA,
![CROI1.gif](../images/030615/030615-10/CROI1.gif)
![CROI2.gif](../images/030615/030615-10/CROI2.gif)
![CROI3.gif](../images/030615/030615-10/CROI3.gif)
![CROI4.gif](../images/030615/030615-10/CROI4.gif)
![CROI5.gif](../images/030615/030615-10/CROI5.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|